Your browser is no longer supported. Please, upgrade your browser.
Kindred Biosciences, Inc.
Index- P/E- EPS (ttm)-0.57 Insider Own4.90% Shs Outstand39.42M Perf Week-11.35%
Market Cap201.05M Forward P/E- EPS next Y-0.75 Insider Trans-11.19% Shs Float37.08M Perf Month-13.26%
Income-21.80M PEG- EPS next Q-0.24 Inst Own69.30% Short Float3.03% Perf Quarter-17.29%
Sales42.20M P/S4.76 EPS this Y65.10% Inst Trans13.97% Short Ratio2.92 Perf Half Y15.58%
Book/sh1.71 P/B2.60 EPS next Y-11.90% ROA-21.30% Target Price- Perf Year-11.71%
Cash/sh1.29 P/C3.44 EPS next 5Y40.00% ROE-29.90% 52W Range3.20 - 6.00 Perf YTD3.25%
Dividend- P/FCF- EPS past 5Y16.60% ROI-22.90% 52W High-27.25% Beta1.27
Dividend %- Quick Ratio9.10 Sales past 5Y- Gross Margin98.10% 52W Low36.41% ATR0.28
Employees63 Current Ratio9.10 Sales Q/Q-28.60% Oper. Margin-47.30% RSI (14)37.66 Volatility5.62% 5.14%
OptionableYes Debt/Eq0.29 EPS Q/Q31.50% Profit Margin-51.70% Rel Volume0.80 Prev Close4.45
ShortableYes LT Debt/Eq0.27 EarningsMay 11 AMC Payout- Avg Volume384.17K Price4.36
Recom2.00 SMA20-9.08% SMA50-8.96% SMA200-1.78% Volume45,435 Change-1.91%
Mar-17-20Downgrade Guggenheim Buy → Neutral
Nov-13-19Reiterated H.C. Wainwright Buy $17.50 → $16
Jul-16-19Downgrade B. Riley FBR Buy → Neutral $18 → $8.50
Jun-11-19Initiated Barclays Overweight $13
May-23-19Initiated Stifel Buy
May-23-19Initiated Guggenheim Buy $11
Mar-07-19Reiterated Lake Street Buy $30 → $12
Nov-08-18Reiterated B. Riley FBR Buy $16 → $21
Jul-24-18Initiated Cantor Fitzgerald Overweight
Dec-27-17Initiated CL King Neutral
Nov-20-17Resumed B. Riley FBR, Inc. Buy $11
Nov-17-17Initiated H.C. Wainwright Buy $9.50
May-24-17Initiated FBR & Co. Outperform $10
Nov-01-16Initiated Ladenburg Thalmann Buy $7.50
Jan-24-14Downgrade BMO Capital Markets Outperform → Market Perform $15
May-03-21 08:42AM  
Apr-29-21 12:34PM  
Apr-28-21 08:32AM  
Apr-26-21 04:53AM  
Apr-20-21 04:03PM  
Mar-16-21 05:35PM  
Mar-09-21 12:30PM  
Mar-08-21 12:30PM  
Mar-02-21 08:31AM  
Feb-25-21 01:37PM  
Feb-16-21 04:02PM  
Feb-09-21 08:32AM  
Jan-28-21 11:31AM  
Dec-27-20 03:05AM  
Dec-22-20 08:31AM  
Dec-21-20 08:31AM  
Dec-11-20 06:49PM  
Dec-02-20 04:02PM  
Nov-12-20 07:15AM  
Nov-11-20 08:32AM  
Nov-09-20 06:25PM  
Nov-02-20 12:31PM  
Oct-28-20 04:05PM  
Oct-08-20 11:37AM  
Oct-07-20 04:24PM  
Oct-06-20 12:50PM  
Sep-28-20 09:28AM  
Sep-16-20 02:57PM  
Sep-09-20 08:02AM  
Aug-31-20 05:00PM  
Aug-27-20 03:30PM  
Aug-05-20 06:25PM  
Jul-29-20 12:33PM  
Jul-28-20 02:58PM  
Jul-23-20 08:32AM  
Jul-16-20 11:00AM  
Jul-08-20 12:00PM  
Jun-29-20 08:51AM  
Jun-19-20 04:30AM  
Jun-14-20 09:47PM  
Jun-08-20 04:02PM  
Jun-03-20 09:53AM  
May-24-20 10:34PM  
May-20-20 07:58AM  
May-13-20 08:30AM  
May-10-20 10:53AM  
May-09-20 11:01PM  
May-07-20 04:02PM  
May-02-20 10:00AM  
Apr-30-20 12:33PM  
Apr-23-20 08:32AM  
Apr-15-20 04:02PM  
Apr-14-20 05:02PM  
Mar-24-20 08:31AM  
Mar-18-20 06:53AM  
Mar-16-20 05:15PM  
Mar-09-20 12:30PM  
Mar-03-20 04:02PM  
Feb-26-20 12:30PM  
Feb-18-20 08:30AM  
Feb-04-20 09:03AM  
Jan-08-20 04:02PM  
Jan-07-20 01:43AM  
Dec-23-19 07:31PM  
Dec-16-19 08:02AM  
Dec-12-19 09:05AM  
Dec-06-19 10:36AM  
Nov-28-19 02:29PM  
Nov-25-19 04:03PM  
Nov-14-19 04:05PM  
Nov-12-19 05:45PM  
Nov-05-19 10:33AM  
Oct-28-19 08:31AM  
Oct-18-19 10:23AM  
Oct-10-19 04:02PM  
Oct-07-19 03:27PM  
Oct-02-19 07:01AM  
Sep-27-19 02:54AM  
Sep-10-19 07:01AM  
Aug-28-19 08:31AM  
Aug-07-19 10:51AM  
Aug-02-19 10:24AM  
Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, engages in developing therapies for pets. Its product pipeline focuses on biologics for a range of indications primarily in dogs and cats. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats; and Zimeta, a dipyrone injection for the control of fever in horses. It also develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-032, a monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; KIND-025 a canine fusion protein targeting IL-4 and IL-13 for atopic dermatitis in dogs; KIND-030, a monoclonal antibody targeting canine parvovirus for the prophylactic indication in dogs; KIND-509, an antibody for canine inflammatory bowel disease in dogs; KIND-510a, a long-acting feline recombinant erythropoietin being developed for the management of non-regenerative anemia in cats; and KIND-511, an anti-tumor necrosis factor treatment for newborn foals. The company was incorporated in 2012 and is headquartered in Burlingame, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bevers DeniseDirectorMar 17Option Exercise0.328,3962,6878,396Mar 18 04:35 PM
Bevers DeniseDirectorMar 17Sale5.008,39641,9970Mar 18 04:35 PM
Bevers DeniseDirectorFeb 22Option Exercise0.324,6221,4794,622Feb 23 04:55 PM
Bevers DeniseDirectorFeb 22Sale5.004,62223,1100Feb 23 04:55 PM
Bevers DeniseDirectorFeb 19Option Exercise0.32525Feb 23 04:55 PM
Bevers DeniseDirectorFeb 19Sale5.005250Feb 23 04:55 PM
Park West Asset Management LLC10% OwnerJan 29Sale5.073,30016,7316,414,985Feb 01 06:00 PM
Park West Asset Management LLC10% OwnerJan 28Sale5.25210,4721,104,9786,418,285Feb 01 06:00 PM
Bevers DeniseDirectorJan 14Option Exercise0.3213,0234,16713,023Jan 15 06:27 PM
Bevers DeniseDirectorJan 14Sale5.0013,02365,1150Jan 15 06:27 PM
Bevers DeniseDirectorJan 07Option Exercise0.3239,06912,50239,069Jan 08 07:03 PM
Bevers DeniseDirectorJan 07Sale5.0039,069195,3490Jan 08 07:03 PM
Bevers DeniseDirectorOct 07Option Exercise0.3212,5084,00312,508Oct 08 09:11 PM
Bevers DeniseDirectorOct 07Sale5.0112,50862,6280Oct 08 09:11 PM
Bevers DeniseDirectorSep 22Option Exercise0.32515165515Sep 24 06:45 PM
Bevers DeniseDirectorSep 22Sale5.005152,5750Sep 24 06:45 PM
Park West Asset Management LLC10% OwnerJun 26Sale4.71115,136542,2916,628,757Jun 30 09:30 PM